Hepatic de novo lipogenesis enzyme abundance

1. Caloric restriction decreases hepatic de novo lipogenesis enzyme abundance in mice.

   “as well as in calorically restricted mice and in two long-lived mutant models.”

   Animalsliver

   The lifespan-extending MEK1 inhibitor trametinib promotes regulation of de novo lipogenesis enzymes by chaperone-mediated autophagy

   Frontiers in aging·25 Jun 2025

More on Caloric restriction

1. Canagliflozin decreases hepatic de novo lipogenesis enzyme abundance in mice.

   “decreased protein abundance of enzymes involved in hepatic de novo lipogenesis (DNL) is characteristic of mice exposed to two anti-aging drugs that modulate glucose homeostasis (acarbose and canagliflozin)”

   Animalsliver

   The lifespan-extending MEK1 inhibitor trametinib promotes regulation of de novo lipogenesis enzymes by chaperone-mediated autophagy

   Frontiers in aging·25 Jun 2025

More on Canagliflozin

1. Acarbose decreases hepatic de novo lipogenesis enzyme abundance in mice.

   “decreased protein abundance of enzymes involved in hepatic de novo lipogenesis (DNL) is characteristic of mice exposed to two anti-aging drugs that modulate glucose homeostasis (acarbose and canagliflozin)”

   Animalsliver

   The lifespan-extending MEK1 inhibitor trametinib promotes regulation of de novo lipogenesis enzymes by chaperone-mediated autophagy

   Frontiers in aging·25 Jun 2025

More on Acarbose